ACHE and Alzheimer disease: However, AChE inhibitors show a limited therapeutic potential, and long-term treatment offers no disease-modifying effects and severe gastrointestinal/cardiovascular side reactions (Sharma et al. 2019), thus suggesting the need for novel multi-target drugs to achieve a therapeutic synergy in AD (Benek et al. 2020; Savelieff et al. 2019).